An agar dilution method was used to measure the minimal inhibitory concentrations of ciprofloxacin (Bay o 9867), norfloxacin, pipemidic acid, and nalidixic acid against 496 clinical isolates. Ciprofloxacin and norfloxacin were active against all species tested (90o minimal inhibitory concentrations c 8 ,ug/ml), although ciprofloxacin was somewhat more active, e.g., against gram-positive cocci. Pipemidic acid and nalidixic acid were active against most of the members of the Enterobacteriaceae, but Klebsiella species and Providencia stuartii were only inhibited by a high concentration of nalidixic acid. 
Nalidixic acid is only used for the treatment of urinary tract infections, owing to its low in vitro activity and to low concentrations in serum. Some new quinoline carboxylic acids have been developed during the last few years. It has been found that the in vitro activity of norfloxacin, one of these derivatives, was superior to that of nalidixic acid (2, 4) . If to 8 ,g/ml), although not as active as against Enterobacteriaceae. The trend in this study that pipemidic acid was somewhat more active in vitro than nalidixic acid was also observed previously (5, 6) . The high activity of norfloxacin against Enterobacteriaceae and the moderate activity against P. aeruginosa and gram-positive cocci was also in agreement with previous studies (1, 2, 4) . As the peak levels of norfloxacin 
